Pharma and hospitals will keep testing the bounds of the 340B program until Congress steps in, a University of Southern California (USC) health policy research fellow predicts in a new white paper.

University White Paper on 340B Says Pharma and Hospitals Will Keep Testing 340B’s Bounds Until Congress Acts

Drug manufacturers and hospitals “will likely continue to test the bounds” of the 340B program until Congress passes legislation addressing multiple concerns about it, a University of Southern California (USC) health policy research fellow says in a new white paper.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
×